This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
False
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
August 17, 2026
3 min read
PRAME-targeted T cells produce a complete response in metastatic nephroblastoma, CAR T cells remain active after a decade, and an in vivo CRISPR screen identifies edits that strengthen solid-tumor activity
August 10, 2026
3 min read
Johnson & Johnson partners with Sail Biomedicines, an FDA advisory committee votes against deramiocel for Duchenne cardiomyopathy, and researchers uncover factors influencing CAR T and CAR NK outcomes
August 7, 2026
7 min read
Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier
July 27, 2026
3 min read
AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck
False
Affiliations:
Specialties:
Areas of Expertise: